Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States

Net, P; Colrat, Florian; Costa, Mafalda Nascimento; Bianic, F.; Thommes, Edward W.; Álvarez, Francisco Blanco

doi:10.1016/j.vaccine.2021.01.016

Cited by 9 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ]. Note: no value indicates that a comparison was not evaluated.…”

Section: Cost-effectiveness Studies With Enhanced Influenza Vaccinesmentioning

confidence: 99%

“…The rVE estimate of 24.2% for HD-TIV/HD-QIV versus TIV/QIV for LCI cases, based on results from the FIM12 RCT [50], was consistently used in CEA comparing HD-TIV/HD-QIV versus TIV/QIV, and used in CEA that indirectly compared the rVE of HD-TIV/HD-QIV versus aTIV/aQIV (Tables 2B and 3B; Figure 2). [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”

Section: Comparison Between Cea For Enhanced and Standard Vaccinesmentioning

confidence: 99%

“…Figure 2. rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV[65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

et al. 2023

View full text Add to dashboard Cite

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals.

show abstract

Section: Cost-effectiveness Studies With Enhanced Influenza Vaccinesmentioning

confidence: 99%

Section: Comparison Between Cea For Enhanced and Standard Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Currently, patients are given one of the three available influenza vaccines: an inactivated virus (e.g., Fluzone), recombinant antigen proteins (FluBlok), or an attenuated virus (FluMist). Each vaccine has to be updated annually to combat the dominant circulating influenza strains, and a mismatched strain can lead to reduced vaccine efficacy as low as 10%, and even a well-matched set of strains can offer an efficacy of only ∼60%. , The seasonal vaccine also induces relatively short-lived protection and is not well-suited against the emergence of novel pandemic influenza strains. , To overcome these issues, higher-dose (high-dose FluZone), , adjuvanted (FluAd), , and intranasal (FluMist) influenza vaccines have all been clinically approved. However, these strategies represent incremental improvements to seasonal vaccines and still do not provide universal protection.…”

Section: Introductionmentioning

confidence: 99%

“…12,13 The seasonal vaccine also induces relatively short-lived protection and is not well-suited against the emergence of novel pandemic influenza strains. 14,15 To overcome these issues, higher-dose (high-dose FluZone), 16,17 adjuvanted (FluAd), 18,19 and intranasal (Flu-Mist) influenza vaccines 20 have all been clinically approved. However, these strategies represent incremental improvements to seasonal vaccines and still do not provide universal protection.…”

Section: ■ Introductionmentioning

confidence: 99%

Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation

et al. 2023

View full text Add to dashboard Cite

The influenza A virus causes substantial morbidity and mortality worldwide every year and poses a constant threat of an emergent pandemic. Seasonal influenza vaccination strategies fail to provide complete protection against infection due to antigenic drift and shift. A universal vaccine targeting a conserved influenza epitope could substantially improve current vaccination strategies. The ectodomain of the matrix 2 protein (M2e) of influenza is a highly conserved epitope between virus strains but is also poorly immunogenic. Administration of M2e and the immunostimulatory stimulator of interferon genes (STING) agonist 3′3′-cyclic guanosine−adenosine monophosphate (cGAMP) encapsulated in microparticles made of acetalated dextran (Ace-DEX) has previously been shown to be effective for increasing the immunogenicity of M2e, primarily through T-cell-mediated responses. Here, the immunogenicity of Ace-DEX MPs delivering M2e was further improved by conjugating the M2e peptide to the particle surface in an effort to affect B-cell responses more directly. Conjugated or encapsulated M2e co-administered with Ace-DEX MPs containing cGAMP were used to vaccinate mice, and it was shown that two or three vaccinations could fully protect against a lethal influenza challenge, while only the surface-conjugated antigen constructs could provide some protection against lethal challenge with only one vaccination. Additionally, the use of a reducible linker augmented the T-cell response to the antigen. These results show the utility of conjugating M2e to the surface of a particle carrier to increase its immunogenicity for use as the antigen in a universal influenza vaccine.

show abstract

Fluzone High-Dose cost saving in elderly population

2021

PharmacoEcon Outcomes News

View full text Add to dashboard Cite

Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States

Cited by 9 publications

References 23 publications

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation

Fluzone High-Dose cost saving in elderly population

Contact Info

Product

Resources

About